MCRB Live signals | Maximize Profits with Getagraph.com

SELL 135541 min ago

@ $1.110

Issued: 14 Feb 2024 @ 09:32

Return: -17.13%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 2.30 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Stats
Today's Volume	1.95M
Average Volume	5.00M
Market Cap	139.32M
EPS	$0 ( 2024-05-08 )
Next earnings date	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.560
ATR14	$0.00600 (0.66%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Von Moltke Lisa	Sell	2 968	Restricted Stock Units
2024-05-15	Von Moltke Lisa	Buy	2 968	Common Stock
2024-05-15	Von Moltke Lisa	Sell	939	Common Stock
2024-05-15	Shaff Eric D.	Buy	7 812	Common Stock
2024-05-15	Shaff Eric D.	Sell	2 435	Common Stock

INSIDER POWER
91.40
Last 99 transactions
Buy: 6 277 293 \| Sell: 298 481

Volume Correlation

Long: -0.37 (neutral)

Short: -0.66 (moderate negative)

Signal:(45.264) Neutral

Seres Therapeutics Inc Correlation

10 Most Positive Correlations
ZUMZ	0.905
FRSH	0.892
IRDM	0.882
SVC	0.882
RRGB	0.875
ALHC	0.873
KNDI	0.872
COMM	0.869
TTEC	0.869
KLXE	0.868

10 Most Negative Correlations
ENTA	-0.894
EDAP	-0.892
JSPR	-0.89
ELEV	-0.888
FBIOP	-0.879
ESTA	-0.877
XLRN	-0.876
RETA	-0.873
CINF	-0.872
JUPW	-0.87

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Seres Therapeutics Inc Correlation - Currency/Commodity

-0.25
( neutral )

-0.62
( weak negative )

0.00
( neutral )

0.78
( moderate )

Seres Therapeutics Inc Financials

Annual	2023
Revenue:	$126.33M
Gross Profit:	$111.21M (88.04 %)
EPS:	$-0.890

FY	2023
Revenue:	$126.33M
Gross Profit:	$111.21M (88.04 %)
EPS:	$-0.890

FY	2022
Revenue:	$7.13M
Gross Profit:	$6.12M (85.91 %)
EPS:	$-2.35

FY	2021
Revenue:	$144.93M
Gross Profit:	$144.93M (100.00 %)
EPS:	$-0.720

Financial Reports:

No articles found.

Seres Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Seres Therapeutics Inc

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.